ArticleNeurology2015
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02659956 (The Pathological Basis of MRI Signal Changes in Multiple Sclerosis), which is not on this map. Cited by 160 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study
Who cites it
160 citing papers in PubMed, 4 syntheses or guidelines pooled it, 301 citations in OpenAlex.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Brain MRI findings in neurologically symptomatic COVID-19 patients: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.NeuroImage. Clinical · 2022Pooled it
- CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic review.NeuroImage. Clinical · 2020Pooled it
- Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis: A 3-Year Longitudinal Study.Neurology(R) neuroimmunology & neuroinflammation · 2022Trial
- Age-related development of meningeal lymphatic vessels in children assessed by 3D T2 FLAIR MRI.Scientific reports · 2026Article
- Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.Journal of neurology · 2026Article
- ODC1 restricts meningeal B cell age-associated-like phenotype and function in multiple sclerosis: A human and experimental study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Lymphotoxin-dependent elevated meningeal CXCL13:BAFF ratios drive gray matter injury.Nature immunology · 2026Article
- Structured assessment of brain MRI in Covid-19-related neurological disease: an international multicentre study.Neuroradiology · 2025Article
- Imaging markers of neuroinflammation in aging and Alzheimer's disease and related dementia: A comprehensive review.Neuroscience and biobehavioral reviews · 2025Review
- Follicle on the Roof: Tertiary Lymphoid Structures in Central Nervous System Autoimmunity.Immunological reviews · 2025Review
- Neurodegeneration correlates of iron-related lesions and leptomeningeal inflammation in multiple sclerosis clinical subtypes.Neuroradiology · 2025Article
- Review
- Senescent cell reduction does not improve recovery in mice under experimental autoimmune encephalomyelitis (EAE) induced demyelination.Journal of neuroinflammation · 2025Article
- First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Predictive Value of Hyperintense Acute Reperfusion Marker in Transient Ischemic Attacks: Stroke Recurrence and TOAST Classification.Brain sciences · 2025Article
- Immune conversations at the border: meningeal immunity in health and disease.Frontiers in immunology · 2025Review
- Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveTo determine the frequency and nature of leptomeningeal contrast enhancement in multiple sclerosis (MS) via in vivo 3-tesla postcontrast T2-weighted, fluid-attenuated inversion recovery (FLAIR) MRI and 7-tesla postmortem MRI-pathology correlation.
methodsBrain MRI, using the postcontrast T2-weighted, FLAIR technique, was prospectively collected in 299 MS cases and 37 age-matched neurologically healthy controls. Expert raters evaluated focal gadolinium enhancement in the leptomeningeal compartment. Two progressive MS cases came to autopsy after in vivo MRI characterization. Pathologic and immunohistochemical examination assessed the association of enhancement with leptomeningeal inflammation and adjacent cortical demyelination.
resultsFocal contrast enhancement was detected in the leptomeningeal compartment in 74 of 299 MS cases (25%) vs 1 of 37 neurologically healthy controls (2.7%; p = 0.001). Enhancement was nearly twice as frequent (p = 0.009) in progressive MS (39/118 cases, 33%) as in relapsing-remitting MS (35/181, 19%). Enhancing foci generally remained stable throughout the evaluation period (up to 5.5 years). Pathology showed perivascular lymphocytic and mononuclear infiltration in the enhancing areas in association with flanking subpial cortical demyelination.
conclusionLeptomeningeal contrast enhancement occurs frequently in MS and is a noninvasive, in vivo marker of inflammation and associated subpial demyelination. It might therefore enable testing of new treatments aimed at eliminating this inflammation and potentially arresting progressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.